The effect of oral and intraurethral trimetazidine use on urethral healing

Abstract

Objective(s): We aimed to study the effect of trimetazidine (TMZ) on urethral wound repair. Materials and Methods: A total of 52 male rats were used; 8 groups were formed: 1-week and 3-week control (C1, C3), sham (S1, S3), oral (OT1, OT3), and intraurethral TMZ (IUT1, IUT3) groups. Serum and urine total antioxidant capacity (TAC), total oxidant capacity (TOC), and 8-hydroxy-deoxy-guanosine (8-OHdG) were studied. Hematoxyline-Eosin was used for the histopathological study. In addition, tumor necrosis factor alpha (TNF-alpha), interleukin 1 alpha, and beta levels were compared across groups by an immunohistochemical method. Results: There were significant differences between C3 and IUT3, OT3 and IUT3 with respect to serum TAC in 3-week groups (P= 0.013; P = 0.001). Serum TOC levels were significantly different between C3 and IUT3; S3 and OT3; and OT3 and IUT3 groups (P = 0.024; P = 0.019; P = 0.000, respectively). Serum 8OHdG levels were significantly different between C3 and OT3 groups (P= 0.033). In the immunohistochemical examination, C1 and OT1; C1 and IUT1; and S1, S3, OT1, OT3, IUT1 groups were significantly different with respect to IL-1 beta staining (P= 0.007; P = 0.000; P= 0.009), while there was a significant difference between C3 and S3 with respect to IL-1 beta (P = 0.000). Conclusion: TMZ increased urinary total oxidant level; while increasing serum TAC levels in the longterm. It also reduced serum TAC levels in urethral use and caused an increase in serum TOC levels with minimal effects on DNA injury and repair. No effect was detected on IL1 alpha and TNF, but partially reduced the effect on IL-1 beta levels.